← Research library

Efficiency of preventive use of bemethyl during long-term voyages

Controlled study in people · 1991

What was studied
298 maritime operators aged 19–38: 148 Bemitil, 150 placebo controls; detailed laboratory and performance tests in a 20-person subset
Main finding
The voyage comparison reported 20% fewer complaints, 6.7% shorter simple-reaction latency, half as many complex-reaction errors and 13.7% greater static-effort endurance in Bemitil-treated sailors. The original also reports laboratory results, adverse reactions and 30-day post-treatment follow-up.

Related evidence maps: Military & occupational ↗

Reported findings and study design

The 298-person voyage comparison reported fewer complaints and better performance measures with Bemitil. Detailed immune and performance measurements were made in a 20-person subset. The paper also reports laboratory changes, adverse reactions and follow-up 30 days after treatment stopped.

298 maritime operators aged 19–38: Bemitil 148, placebo control 150. Detailed resistance and performance testing involved 20 people; their allocation is not stated clearly. Treatment began after one month at sea: 250–500 mg/day for 14 days. Examinations took place before, during and after prolonged voyages.

Population or model 298 maritime operators aged 19–38: 148 Bemitil, 150 placebo controls; detailed laboratory and performance tests in a 20-person subset

Dose, route and schedule

250–500 mg/day for 14 days, beginning after one month at sea. Placebo controls. Measurements before, during and after voyages, including 30 days after treatment stopped. Route not explicitly stated in the inspected Russian methods.

Protocol source ↗ · Original scan, printed page 37

Results · Recovered original journal scan, printed pages 37–39; Tables 1–2 and results visually checked
MeasureResultComparison, timing and statistics
Fatigue, poor mood, headache and insomnia complaints20% lower frequencyAuthors’ reported change in treated sailors; absolute complaint counts are not given · After the course; precise assessment interval is not separately stated
Simple sensorimotor reaction6.7% shorter latencyReported change in treated sailors
Complex sensorimotor reactionErrors reduced twofoldReported change in treated sailors; raw error totals not printed
Static-effort endurance13.7% increaseReported change in treated sailors
Critical flicker fusion and two-minute step-test indexBoth increasedNo numerical amount given in the narrative
Phagocyte uptake capacity40.2% increaseNarrative report after the 14-day course; Table 1 gives 20.08 → 28.15 relative units
Phagocytosis intensity18% increase reported in narrativeThe narrative separately says the degree of phagocytic reaction did not change; Table 1 reports a different measure. These endpoints should not be merged.
Phagocyte loss after 120 minutes24.4% → 14.9%Reported reduction in relative cell loss · p<0.05
Serum lysozyme and bactericidal activityMaintained in treated sailorsControl values fell 11.7% and 6.1%, respectively
Skin bactericidal index18.9% increaseNarrative change after treatment; raw values in Table 1
Skin microbial contamination41% reductionp<0.01
Overall morbidity18.3% treated; 81.7% controlThe paper prints these percentages without raw case counts or a clear denominator. They must not be converted to individual illness risks or a relative-risk reduction.
Respiratory and class-I illnesses29% treated; 42% controlShare of first medical consultations, not the proportion of all sailors who became ill
Allergic reactions2% reportedDenominator and diagnostic criteria not separately tabulated
Reduced appetite2.7% reported
Nausea0.7% reported
Persistence after stopping treatmentMeasurements repeated 30 days after withdrawalAuthors describe resistance and performance as maintained or improved; Tables 1–2 provide the laboratory values
Table 1 · Nonspecific-defense measures
Table 1 · Nonspecific-defense measures
Measure / unitGroupBaselineDay 14 of treatment30 days after withdrawal
Phagocyte uptake capacity / relative unitsControl20.97 ± 1.7519.67 ± 2.1911.54 ± 1.19*
Phagocyte uptake capacity / relative unitsBemitil20.08 ± 0.8728.15 ± 2.17**23.53 ± 2.28**
Degree of phagocytic reaction / relative unitsControl0.66 ± 0.031.33 ± 0.08*1.44 ± 0.09*
Degree of phagocytic reaction / relative unitsBemitil0.84 ± 0.090.82 ± 0.04**0.60 ± 0.06**
Serum lysozyme activity / %Control48.63 ± 1.7842.96 ± 1.15*39.90 ± 0.97*
Serum lysozyme activity / %Bemitil49.68 ± 1.7649.11 ± 1.66**50.15 ± 1.62**
Serum bactericidal capacity / %Control16.27 ± 0.4515.30 ± 0.3114.44 ± 0.30*
Serum bactericidal capacity / %Bemitil16.81 ± 0.3416.89 ± 0.3917.80 ± 0.54**
Skin bactericidal index / %Control70.91 ± 2.2866.05 ± 1.0862.39 ± 1.36*
Skin bactericidal index / %Bemitil66.40 ± 2.5979.0 ± 1.11***82.40 ± 2.01***

Values reproduced as M ± m in the source. * versus baseline, p<0.025; ** versus control, p<0.01; *** versus control p<0.02 and baseline p<0.01. Measures are laboratory endpoints; the original does not specify the 20-person subset split.

Table 2 · Leukocyte cytochemical measures
Table 2 · Leukocyte cytochemical measures
Measure / relative unitsGroupBaselineDay 14 of treatment30 days after withdrawal
GlycogenControl1.62 ± 0.041.58 ± 0.031.51 ± 0.04
GlycogenBemitil1.70 ± 0.051.86 ± 0.02*1.91 ± 0.03*
LipidsControl1.68 ± 0.031.67 ± 0.031.64 ± 0.03
LipidsBemitil1.72 ± 0.021.82 ± 0.02*1.83 ± 0.03*
PeroxidaseControl1.80 ± 0.061.78 ± 0.061.73 ± 0.05
PeroxidaseBemitil1.86 ± 0.051.93 ± 0.03**1.97 ± 0.03*

Values reproduced as M ± m. * versus baseline, p<0.02; ** versus control, p<0.002.

Placebo comparison; randomization and blinding procedures are not described. Performance findings apply to this voyage setting. Morbidity denominators and the detailed-testing subgroup require clarification; no risk reduction has been calculated from the printed morbidity percentages.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Randomization and blinding procedures are not described. The 20-person testing subset is not broken down by treatment arm.
  • The overall morbidity figures, 18.3% and 81.7%, lack underlying counts and an unambiguous denominator; they cannot be treated as individual illness risks.
  • The narrative reports an 18% increase in phagocytosis intensity while a separate degree-of-reaction endpoint is unchanged; distinct measures must not be combined.

Source details

Recovered original journal scan, pages 37–39

Recovered original scan, printed pages 37–39: cohort, regimen, all narrative numerical findings and Tables 1–2 visually checked on 29 October 2026. Morbidity percentages lack clear denominators; no risk reduction was calculated.

All three pages and Tables 1–2 visually checked

Sources checked

Citation

Clinical trial / comparisonRussian-language source

V. S. Novikov, V. N. Bortnovskii, I. A. Shamarin. Efficiency of preventive use of bemethyl during long-term voyages Gig Sanit. (3):37–39

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards